 Equitable comparison between Neoral and Prograf is difficult, as both drugs do not have the same pharmacokinetic profile. Trough or pre-dose level has been used to evaluate drug exposure and make dosage adjustment. Prograf has a more predictive correlation between the trough level and the total area under the curve total drug exposure of the patient than Neoral. C2 monitoring of CSA consists of measuring the drug level 2 hours after ingestion. The correlation of C2 monitoring of Neoral to the area under the curve is similar to the correlation of the trough for Prograf to the area under the curve both R 20.92. C2 monitoring for Neoral has been associated with an increase in efficacy and reduction in toxicity. In this study we will use C2 monitoring for Neoral and trough monitoring for Prograf. Moderate minimization of the calcineurin inhibitor dosage will be used in this study in order to reduce the deleterious effect of the calcineurin inhibitors to the metabolism of glucose. A reduction of approximately 20 of our usual target level will be used. 